Compare Summit Therapeutics Inc (SMMT) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? Summit Therapeutics Inc trades at $17.47 (market cap $13.71B), while ProShares UltraPro S&P500 trades at $155.93 (market cap $5.55B). The key difference: Summit Therapeutics Inc is far larger — about 2.5× ProShares UltraPro S&P500's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and ProShares UltraPro S&P500 for 29 Days on average.
| SMMT | UPRO | |
|---|---|---|
Market Cap | $13.71B | $5.55B |
Volume | 6,173,057 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $157.66 |
52-Week Low | $12.43 | $89.29 |
Typical Hold Time | 16 Days | 29 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
UPRO trades at $155.78, up 0.37% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026, indicating potential income for investors.
The outlook for UPRO is mixed, with technical strength offset by limited fundamental visibility. Risks include market volatility and concentration in top S&P 500 holdings. Upside depends on broader index performance, but investor skepticism amid high valuations may cap gains. Monitoring earnings growth and institutional sentiment is critical for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
